Skip to main content
SpringerLink
Log in

Long-term prognosis of low-risk neuroblastoma treated by surgery alone: an experience from a single institution of China

  • Original Article
  • Published:
World Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Background

Low-risk neuroblastomas have favorable biologic characteristics. Children Oncology Group (COG) proposed that surgical resection of the primary tumor was sufficient. We evaluated the long-term prognosis of surgery alone for patients with low-risk neuroblastoma in China.

Methods

A total of 34 patients with low-risk neuroblastoma were treated in our center between Jan 2009 and Dec 2013. The medical records of these patients were reviewed.

Results

The primary lesion was located in the adrenal gland in 19 patients, the retroperitoneum in 5, the posterior mediastinum in 9 and the neck in 1. The tumor diameters and volumes were 1.80–10.0 cm (average 5.5 ± 2.3 cm) and 1.28–424.10 cm3 (average 58.81 ± 92.00 cm3), respectively. The stages of the patients were as follows: stage I in 25, stage II in 7, and stage IVs in 2. All patients were in the low-risk group according to COG risk stratification criteria. No patients showed MYCN amplification. The primary tumors of all patients were completely resected. Nine adrenal tumors were completely resected by laparoscopy. All patients were successfully followed for 66–115 (average 89.71 ± 16.17) months. Recurrence was observed in 4 patients. In addition to one local recurrence, another three recurrences were metastases. The lesions were effectively controlled in all patients with recurrences. All patients survived, including 28 cases of tumor-free survival; the 4-year overall and event-free survival rates were both 100%.

Conclusions

Surgery alone is a safe and effective treatment strategy for low-risk neuroblastoma. Recurrent lesions may be controlled and treated by rescue chemotherapy and surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017;17:369–86.

    Article  CAS  PubMed  Google Scholar 

  2. Ahmed AA, Zhang L, Reddivalla N, Hetherington M. Neuroblastoma in children: update on clinicopathologic and genetic prognostic factors. Pediatr Hematol Oncol. 2017;34:165–85.

    Article  PubMed  Google Scholar 

  3. Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KK, et al. Children’s Oncology Group’s 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer. 2013;60:985–93.

    Article  PubMed  Google Scholar 

  4. Strother DR, London WB, Schmidt ML, Brodeur GM, Shimada H, Thorner P, et al. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of children’s oncology group study P9641. J Clin Oncol. 2012;30:1842–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the children’s oncology group. J Clin Oncol. 2005;23:6459–65.

    Article  CAS  PubMed  Google Scholar 

  6. Newman EA, Nuchtern JG. Recent biologic and genetic advances in neuroblastoma: implications for diagnostic, risk stratification, and treatment strategies. Semin Pediatr Surg. 2016;25:257–64.

    Article  PubMed  Google Scholar 

  7. Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010;363:1313–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Øra I, Eggert A. Progress in treatment and risk stratification of neuroblastoma: impact on future clinical and basic research. Semin Cancer Biol. 2011;21:217–28.

    Article  PubMed  Google Scholar 

  9. Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, Tickoo SK, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA. 2012;307:1062–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Schneiderman J, London WB, Brodeur GM, Castleberry RP, Look AT, Cohn SL. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children’s Oncology Group. J Clin Oncol. 2008;26:913–8.

    Article  PubMed  Google Scholar 

  11. Bowman LC, Castleberry RP, Cantor A, Joshi V, Cohn SL, Smith EI, et al. Genetic staging of unresectable or metastatic neuroblastomain infants: a pediatric oncology group study. J Natl Cancer Inst. 1997;89:373–80.

    Article  CAS  PubMed  Google Scholar 

  12. Cecchetto G, Mosseri V, De Bernardi B, Helardot P, Monclair T, Costa E, et al. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol. 2005;23:8483–9.

    Article  PubMed  Google Scholar 

  13. Nuchtern JG, London WB, Barnewolt CE, Naranjo A, McGrady PW, Geiger JD, et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children’s Oncology Group study. Ann Surg. 2012;256:573–80.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Yamamoto K, Hanada R, Kikuchi A, Ichikawa M, Aihara T, Oguma E, et al. Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol. 1998;16:1265–9.

    Article  CAS  PubMed  Google Scholar 

  15. Oue T, Inoue M, Yoneda A, Kubota A, Okuyama H, Kawahara H, et al. Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study. J Pediatr Surg. 2005;40:359–63.

    Article  PubMed  Google Scholar 

  16. Coughlan D, Gianferante M, Lynch CF, Stevens JL, Harlan JL. Treatment and survival of childhood neuroblastoma: evidence from a population-based study in the United States. Pediatr Hematol Oncol. 2017;34:320–30.

    Article  CAS  PubMed  Google Scholar 

  17. Dong KR, Li K, Gao JC, Lv ZB, Xiao XM. Treatment results of neuroblastoma with a standardization protocol. Chin J Pedatr Surg. 2009;29:452–5.

    Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Department of Pediatric Surgery, Children’s Hospital of Fudan University, 399 Wanyuan Road, Shanghai, 201102, China

    Wei Yao, Kai Li, Kui-Ran Dong, Shan Zheng & Xian-Min Xiao

  2. National Children’s Medical Center, 399 Wanyuan Road, Shanghai, 201102, China

    Wei Yao, Kai Li, Kui-Ran Dong, Shan Zheng & Xian-Min Xiao

Authors
  1. Wei Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kai Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kui-Ran Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shan Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xian-Min Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YW contributed to conception, design, acquisition, analysis and draft the manuscript. LK contributed to conception, interpretation of data and critically revised the manuscript. DK contributed to acquisition and interpretation of data. ZS contributed to revised manuscript. XX contributed to revised manuscript.

Corresponding author

Correspondence to Kai Li.

Ethics declarations

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Conflict of interest

No financial or nonfinancial benefits have been received or will be received from any party related directly or indirectly to the subject of this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yao, W., Li, K., Dong, KR. et al. Long-term prognosis of low-risk neuroblastoma treated by surgery alone: an experience from a single institution of China. World J Pediatr 15, 148–152 (2019). https://doi.org/10.1007/s12519-018-0205-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12519-018-0205-z

Keywords

Search

Navigation